Ibrutinib, Brentuximab, Blinatumomab na Idelalisib
The American Society of Hematology (ASH) bụ ọkachamara ọkachamara n'ụwa kachasị eche banyere nsogbu na ịgwọ ọrịa ọbara. Kwa afọ, onye kasị mma na onye na-egbukepụ egbukepụ si gburugburu ụwa na-abịa ASH.
N'afọ a, e nwere nnọkọ banyere usoro ọgwụgwọ FDA maka mma maka ọnọdụ hematologic. Emere ya n'ihi na ndị dọkịta chọrọ ịmatakwu banyere ụfọdụ n'ime nkwenye FDA ndị na-adịbeghị anya.
Ndị na-ekwu okwu nyochare ọtụtụ ozi gbasara ọgwụ ọjọọ, gụnyere ibrutinib (Imbruvica), na idelalisib (Zydelig).
Nye ọtụtụ ndị, nzukọ December nke nzukọ ASH na-eje ozi dị ka ihe ngosi maka ọganihu niile e mere n'afọ gara aga na hematology na oncology. Ndị a bụ nanị ole na ole n'ime ihe ndị mmadụ na-ekwu banyere ya.
Ibrutinib (Imbruvica)
Ngwadogwu dị iche iche ma ọ bụ mgbagwoju anya, dị ka enzymes, na-arụ ọrụ na mgbaaka cell-usoro nke mkpụrụ ndụ "nụ" ma zaghachi na akara aka. Tyrosine Kinase (Brton's Tyase) (BTK), bụ enzyme nke na-arụ ọrụ dị mkpa na mmepe B-cell, bụ ihe atụ nke enzyme dị otú ahụ nke na-achịkwa ntinye aka cell. Ibrutinib bụ obere ngwongwo nke na-egbochi BTK enzyme.
Site na igbochi enzyme a, ibrutinib na-etinye aka na ụzọ mgbaàmà na ụfọdụ mkpụrụ ndụ kansa kansa na-adabere. Dabere na ihe ịga nke ọma dị ugbu a, FDA kaputara ibrutinib dịka ọgwụgwọ nke ọma, na-ekere òkè n'ime ịgwọ ọrịa ọjọọ ndị a:
- Ndị na-arịa ọrịa leukemia lymphocytic oge ochie (CLL) bụ ndị natara ọ dịkarịa ala otu ọgwụgwọ mbụ
- Ndị ọrịa na-arịa ọbara ọbara lymphocytic oge ochie (CLL) na nhichapụ 17p
- Mantle cell lymphoma (MCL) ọrịa ndị natara ọ dịkarịa ala otu tupu ọgwụgwọ
Ibrutinib bu uro nke anare ya otu ubochi ma anagide ya. A na-enyocha onye ọrụ ahụ na ọgwụgwọ ndị ọzọ na-arịa ọrịa, ma naanị ya na ọgwụgwọ dị iche iche.
Idelalisib (Zydelig)
Idelalisib bụ FDA-kwadoro maka ndị mmadụ na-alaghachi na- arịa ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) , weghachite lymphoma lymphoma B-cell non-Hodgkin (FL), ma weghachite obere lymphocytic lymphoma (SLL, ụdị ọzọ nke lymphoma na-abụghị Hodgkin).
Nkwado dabeere na nchoputa nke ikpe nke mmadụ 220 na-ahapụ CLL, bụ ebe a na-emeghị atụmatụ ọgwụ kemịcha. Usoro ahụ bụ idelalisib + rituximab ma ọ bụ placebo + rituximab. Ikpe ahụ gosiri na pasent 82% dị n'ihe ize ndụ nke ịrịa cancer na idelalisib, n'ihi ya, ha kwụsịrị ya n'isi, na-enye ndị ọrịa placebo + rituximab ihe niile banyere idelalisib ma nye ha ọgwụ ọhụrụ. Ndị niile na-arịa ọrịa na-anọ n'ụlọ ọgwụ rituximab + ikpe ahụ wee malite inweta idelalisib.
Brentuximab vedotin (Adcetris)
Onye ọrụ a bụ injection maka infusion. Brentuximab vedotin nwere usoro na-adọrọ mmasị nke ihe. Ọ bụ mgbochi a na - emepụta ihe - ya na onye na - elekọta ndị na - enyere aka na - egbu mkpụrụ ndụ cancer mgbe ha ruru ha. A na-atụkwasị ya na protein nke a na-akpọ CD30, nke dị na lymphoma Hodgkin oge ochie (HL) nakwa na lymphoma cellular anaplastic (sALCL).
Ọmụmụ ihe a na-atụle na ASH bụ nke mbụ na lymphoma iji gosipụta na mgbakwunye nke ọgwụ na-arụzi mgbe a sụgharịrị ya nwere ike ime ka mma nwekwuo ọrịa.
N'ime ikpe ikpe AETHERA, ihe dịka 63% nke ndị ọrịa lymphoma dị elu bụ ndị e mesoro ya na ọgwụ ahụ nwetara nhụsịrị ndụ na-enweghi ọganihu nke ọnwa 24 ma e jiri ya tụnyere 51% nke ndị ọrịa natara placebo.
Blinatumomab (Blincyto)
Nke a bụ ọgwụ mbụ nke ọgwụ BITE (dịka T-Cell Teta Engager). O gosiputawo ihe dị mkpa na ọrịa B-cell na- arịa ọrịa kansa ọbara lymphocytic (ALL) ndị ọrịa na-enwe obere ọrịa na-edozi ahụ mgbe a gwọchara ya , dịka ndị na-eme nnyocha na ASH si kwuo. Blinatumomab kpochapụrụ mkpụrụ ndụ cancer cancer site na 78% nke ndị ọrịa 112.
Dị ka Ụlọ Ọrụ Na-ahụ Maka Ọrịa Cancer ahụ si kwuo, blinatumomab bụ mgbochi a na-emepụta nke nwere ike iji kpalie usoro ahụ ji alụso ọrịa ọgụ ma na- aga mgbe ọrịa cancer na-eme ihe omume antineoplastic.
FDA kwadoro blinatumomab iji mesoo ndị ọrịa na chromosome Philadelphia -ezigbo lymphoblastic leukemia (B-cell ALL) nke B-cell, nke bụ ụdị ihe niile.
Lelee Niccola Gokbuget, MD, kọwaa otú blinatumomab si arụ ọrụ.
Ụgbọ ala na-eduga ná nkwụsị niile
Data ogologo oge site na ịnwale site na iji mkpụrụ ndụ T receptor chimeric (CAR) T gosiri na mkpụrụ ndụ ndị a na-edegharị na-anọchi anya ruo oge ụfọdụ, na-arụ ọrụ ha, na-eduga na nkwụsị ogologo oge. Ọtụtụ n'ime ndị ọkà mmụta sayensị nwere nchekwube maka ụdị ọgwụgwọ a maka ọrịa dịgasị iche iche nke siri ike ịmalite.
Rịba ama na mmetụta dị n'akụkụ
N'iba ama, ndị ọrụ a nile nwere mmetụta ndị ọzọ, ụfọdụ n'ime ha nwere ike ịdị njọ, ụfọdụ n'ime ha nwekwara ike ịbụ ndị amabeghị. Dịka ọ na-eji ọgwụgwọ nile, mkpebi nke ịgwọ ọrịa na-emetụta ihe a maara banyere ihe ndị nwere ike ịdaba na uru nke ọgwụgwọ na ihe onye ọrịa.
Isi ihe
National Cancer Institute. Ozi nlekọta Blinatumomab. http://www.cancer.gov/drugdictionary?cdrid=487684. Enweta December 2014.
MedPageToday. http://www.medpagetoday.com/MeetingCoverage/ASHHematology/48998. Enweta December 2014.